		JAN 1 n	2000					Sheet 1 of 3
FORM PTO 1449 (REV 2-32)				F	File No. 98-10D1		Serial No. 09/371,333	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT RECEIVED Applicant(s): Wen-feng Xu et al.								
JAN 1 3 2051ing Date: Group: 1646 August 10, 1999								
			U.	.S. PATENT D			-	
EXAMINER INITIAL	<u> </u>	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	09/032,397	N/A	Coughlin and Kahn				
	 		 					
			Ĺ'					
			 					
				EIGN PATENT	DOCUME	NTS		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	 		 	 				
	\vdash	ļ	 				 	
(OTHE	ER DOCUM	ENTS (Inc	luding Author	r, Title, Dat	te, Pertin	ent Pateni	ts, Etc.)
2	A2		Vu et al., "Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation," Cell 64:1057-1068, March 22, 1991.					
n	A3_		Rasmussen et al., "cDNA cloning and expression of a hamster α-thrombin receptor coupled to Ca ²⁺ mobilization," FEBS Lett. 288:123-128, August, 1991.					
1	_A4		Nystedt et al., "Molecular cloning of a potential proteinase activated receptor," <u>Proc. Nat'l Acad.</u> <u>Sci. USA</u> 91:9208-9212, September 1994.					
1	A5_		Vu et al., "Domains specifying thrombin-receptor interaction," Nature 353:674-677, October 17, 1997.					
	A6		Connolly et al., "Role of the thrombin receptor in development and evidence for a second receptor," Nature 381:516-519, June 6, 1996.					
2	A7		Coughlin, "Protease activated receptors start a family," <u>Proc. Nat'l Acad. Sci. USA</u> 91:9200-9202, September, 1994.					
2	A8		Molino et al., "Endothelial cell thrombin receptors and PAR-2," J. Biol. Chem. 272:11133-11141, April 25, 1997.					
Examiner	76	1_ (Date consider	ed ?—	200	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	-	Fig. 00	DE O L MAT	Y			Sheet 2 of 3	
FORM PTO 1449 (REV 2-32)					File No. 98-10D1		Serial No. 09/371,333	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Applicant(s): Wen-feng Xu et al.			
					Filing Date: August 10, 1999		Group: 1646	
			U.	S. PATENT DOCUMEN	NTS			
		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE 02/27/98	
							02/2/196	
-								
			FOR	EIGN PATENT DOCUM	MENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUBCL		SS FILING DATE IF APPROPRIATE	
						<u> </u>		
	OTHE	ER DOCUM	ENTS (Inc	cluding Author, Title, D	ate, Pertir	ent Paten	its, Etc.)	
9/	_B1			"Specificity of the thrombinace," Nature 368:648-651, Apri		agonist pep	tide is defined by its	
	B2	Ishi	i et al "Inhi	bition of thrombin recentor sig	maling by a G	-protein coun	oled receptor kinase," J.	
1 9/		<u>Bio</u>	Ishii et al., "Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase," <u>J. Biol. Chem.</u> 269:1125-1130, January 14, 1994.					
9/	ВЗ		Probst et al., "Sequence alignment of the G-protein coupled receptor superfamily," <u>DNA Cell Biol.</u> 11:1-20, 1997.					
V	B4		Ishihara et al., "Protease-activated receptor 3 is a second thrombin receptor in humans," Nature 386:502-506, April 3, 1997.					
	B5	EST	EST from Incyte Pharmaceuticals, Inc., 373881.					
4/	<u> </u>							
1 2	B6	EST	EST from Incyte Pharmaceuticals, Inc., 2189250.					
0/	B7	ES	EST from Incyte Pharmaceuticals, Inc., 2899749.					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Date considered

•		•		سر تا			Sheet 3 of 3		
FORM PTO 1449 (REV 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT					File No. 98	File No. 98-10D1			
					Applicant(s): Wen-feng Xu et al.				
						Filing Date: August 10, 1999			
-		-		U.S. PATENT DO	CUMENTS		,		
EXAMINER INITIAL	DOCUMENT NUMBER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
			 						
			<u> </u>						
						+			
			+			1			
×			-						
			†						
			<u> </u>						
			FO	REIGN PATENT I	DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		·				 			
			<u> </u>						
						1			
	OTH			ncluding Author,		nent Pate	nts, Etc.)		
WU	C1	ES	T from Incy	te Pharmaceuticals, Inc.	, 3218437.		<u> </u>		
/ , -									

		+							
		1							

Examiner

4

Date considered

11-3-2000

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.